Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
    • Transskriptioner
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Cereno Scientific

6,77 SEK

+1,20 %

Mindre end 1K følgere

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Investorkonsensus
Sammenligne
+1,20 %
-3,70 %
-3,22 %
-8,33 %
-26,94 %
+33,17 %
+147,80 %
+256,05 %
+12,54 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Læs mere
Markedsværdi
2,11 mia. SEK
Aktieomsætning
3,94 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
27.2
2026

Årsrapport '25

29.4
2026

Delårsrapport Q1'26

17.6
2026

Generalforsamling '26

Alle
Selskabspræsentationer
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper
Pressemeddelelse28.1.2026, 12.02

Cereno Scientific to Present CS014 Data and Participate in Panel at Scientific Conference PVRI 2026 Dublin

Cereno Scientific
Pressemeddelelse16.1.2026, 06.45

Cereno Scientific: Invitation to Capital Markets Day 2026

Cereno Scientific
Pressemeddelelse14.1.2026, 12.15

Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases

Cereno Scientific

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Eksterne analyser13.1.2026, 06.18

Cereno Scientific: Entering a value inflection phase - Edison

We refresh our investment case for Cereno Scientific as the company enters a key value inflection period, with its lead asset CS1 expected to initiate a Phase IIb study in Q226, followed by Phase II development of CS014 shortly thereafter. With the FDA...

Cereno Scientific
Selskabsmeddelelse8.1.2026, 09.45

Cereno Scientific Receives approximately SEK 5 million Through Exercise of 728,957 Warrants by Arena Investors, LP

Cereno Scientific
Pressemeddelelse18.12.2025, 13.50

Cereno Scientific's Board of Directors and Management Enter Lock-up Agreements

Cereno Scientific
Pressemeddelelse18.12.2025, 09.00

Cereno Scientific to Host Capital Markets Day on February 5, 2026

Cereno Scientific
Pressemeddelelse12.12.2025, 06.45

Cereno Scientific to Attend JPM Week and Biotech Showcase in San Francisco, US, on January 12-18, 2026

Cereno Scientific
Selskabsmeddelelse8.12.2025, 21.25

Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)

Cereno Scientific
Pressemeddelelse3.12.2025, 07.00

Cereno Scientific to Present New Data of CS014 at the Pharmacology 2025 on December 15-18

Cereno Scientific
Selskabsmeddelelse30.11.2025, 09.17

Correction: Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027

Cereno Scientific
Pressemeddelelse28.11.2025, 18.31

Cereno Scientific: Major shareholders and new investors back the Company's long-term strategy with equity investment at a premium

Cereno Scientific
Selskabsmeddelelse28.11.2025, 18.30

Cereno Scientific Secures SEK 100m in Directed Share Issue and Loan Financing of SEK 350m Reaching Milestones in Q4-2027

Cereno Scientific
Selskabsmeddelelse27.11.2025, 06.30

Cereno Scientific Publishes Interim Report for Q3 2025 (July 1 - September 30, 2025)

Cereno Scientific
Selskabsmeddelelse11.11.2025, 06.45

Cereno Scientific Receives SEK 4 million Through Exercise of 600,000 Warrants by Arena Investors, LP

Cereno Scientific
Pressemeddelelse10.11.2025, 12.40

BioStock: Cereno Scientific takes the next step towards phase IIb study in PAH

Cereno Scientific
Pressemeddelelse10.11.2025, 06.45

Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. FDA

Cereno Scientific
Pressemeddelelse15.10.2025, 05.45

Cereno Scientific to Participate at BIO-Europe Fall 2025 in Vienna - the Global BioPharma Partnering Event

Cereno Scientific
Pressemeddelelse24.9.2025, 06.00

Cereno Scientific Participates at Partnering and Investor Conference Nordic Life Science Days 2025

Cereno Scientific
Selskabsmeddelelse15.9.2025, 09.15

Cereno Scientific Announces Conversion of All Remaining Convertibles Following Request by Fenja Capital II A/S and Arena Investors, LP

Cereno Scientific
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.